| 51 |
27721325 | Degradable Cross-Linked Nanoassemblies as Drug Carriers for Heat Shock Protein 90 Inhibitor 17-N-Allylamino-17-demethoxy-geldanamycin. | 2011 Sep 26 |
1 |
| 52 |
19662650 | BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy. | 2010 Mar 1 |
1 |
| 53 |
19948165 | Protection of oligodendrocyte precursor cells by low doses of HSP90 inhibitors in cell culture. | 2010 Sep |
1 |
| 54 |
20231781 | Combination therapy for hepatitis C virus with heat-shock protein 90 inhibitor 17-AAG and proteasome inhibitor MG132. | 2010 Mar 9 |
1 |
| 55 |
20423228 | Therapeutic effects of radiolabeled 17-allylamino-17-demethoxygeldanamycin on human H460 nonsmall-cell lung carcinoma xenografts in mice. | 2010 Apr |
1 |
| 56 |
20618338 | Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma. | 2010 Aug |
2 |
| 57 |
20646760 | 17-N-Allylamino-17-demethoxygeldanamycin induces a diverse response in human acute myelogenous cells. | 2010 Nov |
1 |
| 58 |
20669973 | MEK inhibition potentiates the activity of Hsp90 inhibitor 17-AAG against pancreatic cancer cells. | 2010 Oct 4 |
1 |
| 59 |
20828379 | 17-Allylamino-17-demethoxygeldanamycin induces downregulation of critical Hsp90 protein clients and results in cell cycle arrest and apoptosis of human urinary bladder cancer cells. | 2010 Sep 9 |
1 |
| 60 |
20861078 | Mineralocorticoid receptor degradation is promoted by Hsp90 inhibition and the ubiquitin-protein ligase CHIP. | 2010 Dec |
1 |
| 61 |
18682579 | Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells. | 2009 Apr |
1 |
| 62 |
18793708 | VIP-grafted sterically stabilized phospholipid nanomicellar 17-allylamino-17-demethoxy geldanamycin: a novel targeted nanomedicine for breast cancer. | 2009 Jan 5 |
1 |
| 63 |
18820127 | 90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1. | 2009 Jan |
1 |
| 64 |
19162015 | High cytotoxic sensitivity of the oligodendrocyte precursor cells to HSP90 inhibitors in cell cultures. | 2009 Apr |
1 |
| 65 |
19244114 | Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells. | 2009 Mar 1 |
2 |
| 66 |
19383903 | Transcription inhibition of heat shock proteins: a strategy for combination of 17-allylamino-17-demethoxygeldanamycin and actinomycin d. | 2009 May 1 |
1 |
| 67 |
19405528 | Potent cytotoxic C-11 modified geldanamycin analogues. | 2009 May 28 |
1 |
| 68 |
19514085 | Candidate therapeutic agents for hepatocellular cancer can be identified from phenotype-associated gene expression signatures. | 2009 Aug 15 |
1 |
| 69 |
19860734 | Ansamycin inhibitors of Hsp90: nature's prototype for anti-chaperone therapy. | 2009 |
1 |
| 70 |
20201223 | Long-acting, multi-targeted nanomedicine: addressing unmet medical need in acute lung injury. | 2009 Dec |
1 |
| 71 |
17909811 | A limited sample model to predict area under the drug concentration curve for 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite 17-(amino)-17-demethoxygeldanomycin. | 2008 Jan |
1 |
| 72 |
18199556 | Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel. | 2008 Jan 15 |
1 |
| 73 |
18375819 | BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors. | 2008 Apr |
1 |
| 74 |
18410797 | Emerging agents in the treatment of anthracycline- and taxane-refractory metastatic breast cancer. | 2008 Apr |
1 |
| 75 |
18519777 | A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies. | 2008 Jun 1 |
1 |
| 76 |
18827603 | Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma. | 2008 Oct |
1 |
| 77 |
18852129 | Cisplatin abrogates the geldanamycin-induced heat shock response. | 2008 Oct |
1 |
| 78 |
18974397 | 17-Allylamino-17-demethoxygeldanamycin down-regulates hyaluronic acid-induced glioma invasion by blocking matrix metalloproteinase-9 secretion. | 2008 Nov |
1 |
| 79 |
19014541 | Heat shock protein-90-alpha, a prolactin-STAT5 target gene identified in breast cancer cells, is involved in apoptosis regulation. | 2008 |
1 |
| 80 |
19026643 | HSP90 is required for TAK1 stability but not for its activation in the pro-inflammatory signaling pathway. | 2008 Dec 10 |
1 |
| 81 |
19066127 | Effects of Hsp90 inhibition in neuroblastoma: analysis of drug sensitivity, target modulation and the influence of bone marrow microenvironment. | 2008 |
1 |
| 82 |
17079230 | The platelet-derived growth factor receptor alpha is destabilized by geldanamycins in cancer cells. | 2007 Jan 5 |
1 |
| 83 |
17221841 | The Hsp90 inhibitor, 17-AAG, prevents the ligand-independent nuclear localization of androgen receptor in refractory prostate cancer cells. | 2007 Apr 1 |
1 |
| 84 |
17327415 | Hsp90 regulates the Fanconi anemia DNA damage response pathway. | 2007 Jun 1 |
1 |
| 85 |
17332306 | Synergism between etoposide and 17-AAG in leukemia cells: critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51. | 2007 Mar 1 |
1 |
| 86 |
17363505 | Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo. | 2007 Mar |
1 |
| 87 |
17363533 | Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study. | 2007 Mar 15 |
1 |
| 88 |
17404095 | Evaluation of plasma insulin-like growth factor binding protein 2 and Her-2 extracellular domain as biomarkers for 17-allylamino-17-demethoxygeldanamycin treatment of adult patients with advanced solid tumors. | 2007 Apr 1 |
1 |
| 89 |
17610208 | Proteome-wide changes induced by the Hsp90 inhibitor, geldanamycin in anaplastic large cell lymphoma cells. | 2007 Aug |
1 |
| 90 |
17949452 | Rituximab and 17-allylamino-17-demethoxygeldanamycin induce synergistic apoptosis in B-cell chronic lymphocytic leukaemia. | 2007 Dec |
1 |
| 91 |
18048823 | Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. | 2007 Dec 1 |
2 |
| 92 |
16213582 | The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level. | 2006 May |
1 |
| 93 |
16311509 | Pharmacological induction of Hsp70 protects apoptosis-prone cells from doxorubicin: comparison with caspase-inhibitor- and cycle-arrest-mediated cytoprotection. | 2006 Sep |
1 |
| 94 |
16482209 | Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C. | 2006 Apr |
1 |
| 95 |
16544941 | Reaction of geldanamycin and C17-substituted analogues with glutathione: product identifications and pharmacological implications. | 2006 Mar |
1 |
| 96 |
16634649 | Dihydroquinone ansamycins: toward resolving the conflict between low in vitro affinity and high cellular potency of geldanamycin derivatives. | 2006 May 2 |
1 |
| 97 |
16827149 | In vitro combined modality treatment of prostate carcinoma cells with 17-(allylamino)-17-demethoxygeldanamycin and ionizing radiation. | 2006 May-Jun |
1 |
| 98 |
16832603 | A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. | 2006 Nov |
1 |
| 99 |
16923571 | Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma. | 2006 Jul |
1 |
| 100 |
17083915 | Inhibition of homologous recombination repair in irradiated tumor cells pretreated with Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin. | 2006 Dec 22 |
2 |